Barclays
COCP icon

Barclays’s Cocrystal Pharma COCP Stock Holding History

Barclays’s Portfolio COCP Stock Details COCP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16
Closed -$20 – 5308
2025
Q3 		$20 Buy
+16
New +$25 ﹤0.01% 5359
2022
Q1 		– Sell
-13
Closed – – 5034
2021
Q4 		$0 Sell
13
-2,209
-99% -$22.6K ﹤0.01% 4193
2021
Q3 		$28K Buy
2,222
+1,584
+248% +$20.9K ﹤0.01% 4285
2021
Q2 		$10K Sell
638
-737
-54% -$11.2K ﹤0.01% 4625
2021
Q1 		$23K Buy
+1,375
New +$27.9K ﹤0.01% 4343

Other funds holding COCP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Barclays's COCP Position: Q4 2025 in Review

Barclays sold out of Cocrystal Pharma (COCP) in Q4 2025, closing a stake of 16 shares — an estimated $20 sold.

Barclays first reported a position in COCP in Q1 2021 and held it in 5 quarters. The position peaked at $28K in Q3 2021. 28 funds tracked by Wall St. Rank hold COCP as of Q4 2025.

  • Barclays reported no remaining Cocrystal Pharma position as of Q4 2025 after selling out during the quarter.
  • Barclays sold 16 Cocrystal Pharma shares in Q4 2025, an estimated $20.
  • Barclays first reported a position in Cocrystal Pharma in Q1 2021 and held it in 5 quarters.
  • Barclays's Cocrystal Pharma position peaked at $28K in Q3 2021.
  • 28 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q4 2025.

Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.